Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

February 28, 2013

Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
DRUG

MEGF0444A

Intravenous repeating dose

DRUG

bevacizumab

Intravenous repeating dose

DRUG

carboplatin

Intravenous repeating dose

DRUG

paclitaxel

Intravenous repeating dose

DRUG

placebo

Intravenous repeating dose

Trial Locations (42)

1121

Budapest

1125

Budapest

2065

St Leonards

2800

Tatabánya

4029

Herston

5011

Woodville South

8000

Székesfehérvár

12208

Albany

13273

Marseille

13915

Marseille

17033

Hershey

22927

Großhansdorf

30060

Marietta

31059

Toulouse

32904

Orlando

33603

Tampa

33719

St. Petersburg

34952

Port Saint Lucie

35205

Birmingham

37203

Nashville

43219

Columbus

44805

Saint-Herblain

45122

Essen

46260

Indianapolis

55337

Burnsville

69373

Lyon

71913

Hot Springs

72037

Le Mans

75571

Paris

76104

Fort Worth

78731

Austin

82131

Gauting

89148

Las Vegas

90404

Santa Monica

97239

Portland

98684

Vancouver

67214-3728

Wichita

656 53

Brno

708 52

Ostrava - Poruba

06120

Halle

85-796

Bydgoszcz

80-952

Gdansk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY